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others (3.9%).[3] Morbidity and mortality are high because most affected individuals cannot access renal replacement therapy and hemodialysis (HD). Other contributory factors for this exacerbated state include but not limited to late presentation, limited renal replacement therapy and its unaffordability, the absence of kidney disease prevention programs, and the poor literacy level.[3]CKD has been defined by the Kidney Disease Outcome Initiative as kidney damage or glomerular filtration rate (GFR) of <60 mL/min/1.73 m2 for 3 months or more, due to any cause.[4] CKD is a disease of multiple etiology characterized by progressive and irreversible deterioration of renal function due to the slow destruction of renal parenchyma, eventually terminating in death when sufficient numbers of nephrons have been damaged. 
INTRODUCTIONChronic kidney disease (CKD) is emerging as a major global health problem with huge economic burden both on the affected families of patients and health-care delivery systems. CKD continue to increase in low-income to middle-income countries (LMICs) due to the significant increase in non-infectious diseases and infectious conditions, juxtaposed with under-equipped health-care systems.[1] Previous studies in Nigeria have put the prevalence of CKD between 1.6% and 12.4% with a high prevalence of risk factors observed in various studies among different groups.[2] An epidemiological study by Arogundade 
et al.[3] reported major causes of CKD in Nigeria; hypertension (29.8%), chronic glomerulonephritis (27.8%), diabetes mellitus (3.1%), obstructive uropathy (5%), unknown (30%), and 
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Chronic glomerulonephritis and interstitial nephritis remain among the principal causes of CKD, reflecting the high prevalence of infections that affect the kidneys. Several parasitic infections cause CKD through ureteric obstruction (schistosomiasis), interstitial nephritis (kala-azar), and glomerulonephritis (malaria).[5]Hematological derangements are common in CKD due to relative deficiency/reduction in erythropoietin (EPO) production and other factors such as increased hemolysis, suppression of bone marrow erythropoiesis, and hematuria and gastrointestinal blood loss.[6] The prevalence of anemia correlates with the severity (stages) of kidney impairment. It ranges from about 1% in Stage 2 of CKD to almost 100% in end-stage renal disease.[7] The deficiencies of iron, Vitamin B12, and folate as a result of nutritional insufficiency or due to increased blood loss, aside EPO production, are contributory factors to abnormal hematological indices in CKD. EPO potentiates the effect of megakaryocyte colony stimulating factors, acetylhydrolase (PAF-AH), and paraoxonase (PON1); thus, in chronic renal disease, the impaired EPO secretion leads to a decrease in platelet count.[6,8] The detection of receptors for EPO in megakaryocytes is comprehensible because EPO levels can affect platelet level and because of extensive homology between EPO and thrombopoietin, EPO act as the major humoral regulator of platelet mass.[6,8] As high as 20% of HD patients may experience a fall in total leukocyte count. This is due to exposure of blood to artificial membranes in the dialyzer during dialysis. This exposure may result into in vivo complement activation (C3a or C5a) which in turn induces neutrophil aggregation and adherence to the endothelial surface with resultant fall in total leukocyte count.[9]HD is the most common modality for renal replacement treatment in Sub-Sahara Africa where accumulated toxic solutes (mainly urea and creatinine) and fluids are removed from a patient who has total or near total loss of kidney function using HD machine. The patient blood is passed through an extracorporal circuit and pumped across an artificial semi-permeable membrane to bring the blood into contact with the dialysate (dialysis fluid). The principle of HD depends on utilization of dialysis solution, HD dilution, and ultra-filtration. Nigeria is the third with the highest number (6.3 per million population) of patients on hemodialysis in South Africa and Kenya.[10] Whether or not HD impacts on the average life expectancy of CKD patients has been debated Stokes[11] reported that the <3 years average life expectancy has not changed in 20 years. This may not be unconnected with the short- and long-term side effects and complications associated with the HD. Recently, studies illuminating under-reported hematological and biochemical indices at pre- and post-dialysis stages, as well as comorbidities are emerging.[12] There is a paucity of such data in Yola, Nigeria. Hence, this study sought to determine hematological changes and to compare the levels of the changes in pre-dialysis and post-dialysis stages in patients with CKD attending Dialysis Centre in a Tertiary Hospital in Yola, Nigeria.
MATERIALS AND METHODS
Study AreaThe study was carried out at the Dialysis Centre of Federal Medical Center, Yola, Adamawa state, Nigeria. Yola is in North Eastern Nigeria. The hospital serves as a referral site for the other health 
institutions especially from the 21 Local Government Areas of the state and the neighboring communities. The study area is defined by longitude 13.50 E and latitude 110 N. The characteristic vegetation is that of Sub-Sudan and Guinea savannah with an average annual rainfall of 79 mm and 197mm in the northern and southern part of the state and temperature range of 15°C–39.7°C. There are two distinct seasons: The wet and the dry seasons and the former takes place between April and October, while the latter occurs from November to March. The state is multiethnic with a population of about 3.2 million; Christianity and Islam are the major religions.
Study ParticipantsA total of 100 kidney disease patients attending dialysis treatment at the hospital were used as research subject while fifty 50 individuals without kidney disease were used as control group. Ethical approval was obtained from the Ethics and Research Committee of the Hospital.
Sample Collection and Processing5 ml of blood specimen was aseptically collected into a lavender-top vacutainer tube containing K2-Ethylenediaminetetraacetic acid. The blood was gently mixed with EDTA anticoagulant to avoid blood clot formation. Alternatively, a mechanical mixer was used for at least 5 min. All the venous blood samples were analyzed within 24 h of collection.
Laboratory Analytical MethodAll hematological parameters comprising PCV, hemoglobin concentration (Hb), platelets count, red cell indices (Mean corpuscular volume, mean corpuscular Hb, and mean corpuscular Hb concentration), and differential leukocyte count were analyzed using standard methods as provided by five parts Beckman Coulter hematology auto analyzer.
Statistical AnalysisAll values were expressed as mean ± standard deviation (SD). Data obtained were subjected to one-way ANOVA and t-test using Statistical Package for the Social Sciences (SPSS) version 22. 
P ≤ 0.05 (P ≤ 0.05) was considered statistically significant.
RESULTSThe hematological profile of 100 HD patients and 50 control subjects was analyzed. The pre- and post-dialysis samples were analyzed, and comparison was made between the pre-dialysis and control group, then between the pre- and the post-dialysis. Table 1 showed the prevalence of kidney disease patients in different age groups attending dialysis center of the Federal Medical Centre, Yola, Nigeria where the highest proportion (29%) was observed at age group 51–55 years while the lowest proportion (1%) was recorded at 76–80 years of age. Table 2 showed the mean age and gender distribution of the HD patients, the mean age of males was 56.9 ± 2.7 years while that of female was at 42.5 ± 6.2 and the gender ratio in male to female HD patients was 2.6:1. Table 3 showed the hematological profile of the HD patients at pre-dialysis and post-dialysis stages compared with control subjects. The patients at pre-dialysis have significantly reduced mean ± SD of Hb concentration (6.3 ± 1.8 g/dl), red blood cell (RBC) count (2.1 ± 1.3 × 106/ul), and platelet count (186 ± 28.2 × 103/ul) compared to control group which had 12.2 ± 1.4 g/dl, 4.4 ± 0.2 × 106/ul, and 
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350.5 ± 82.2 × 103/ul, respectively; while in contrast had higher lymphocyte count (39.7 ± 3.0%) when compared with the control group (37.0 ± 4.2%). At post-dialysis stage, PCV (27.1 ± 5.0%), Hb concentration (7.8 ±1.2 g/dl), RBC count (2.9 ± 0.5 × 106/ul), and neutrophil (58.3 ± 3.8%); significantly increased compared with pre-dialysis stage with PCV (24.1 ± 2.0%), Hb concentration (6.3 ± 1.8 g/dl), RBC count (2.1 ± 1.3 × 106/ul), and neutrophil (54.7 ± 3.2%).
DISCUSSIONHD is the most common modality for renal replacement treatment in Sub-Sahara Africa where near normal kidney function is achieved in CKD patients with the use HD machine.[13] There is a reluctant improvement in the life expectancy of CKD patients on HD over a long period of time and thus the need to elucidate hematological comorbidity associated with CKD. Previous studies depicted hematological alterations in the HD patients and emerging corrective modalities may help improve life expectancies and ameliorate costs and other burdens associated with CKD. This study was carried out to determine the pre- and post-dialysis hematological indices of CKD patients attending dialysis center in a tertiary hospital in Yola, Nigeria.This study found out that most (29%) of HD patients in Yola are within the age of 51–55 years. This is similar to what obtained in previous studies in Sudan [14] and Southern Nigeria.[15] However, studies in India[16] and Democratic Republic of Congo [17] reported younger adults. However, due to the high cost of maintenance HD and prevailing poverty, greater proportion of CKD patients may not have been captured as they may not afford the dialysis fees.[18] Nevertheless, young adults within the age of 20–50 years in Sub-Saharan Africa mostly develop CKD due to hypertension and glomerulonephritis.[19] The male HD patients were found to be more than their female counterparts with the male to female ratio of 2.6:1. A large meta-analysis performed on a global consortium of over 2 million participants showed that the risks of all-cause mortality and cardiovascular-related mortality were higher among mean for all levels of GFR.[20] Sex hormones are thought to play a major role in the biological mechanisms associated with variability in CKD prevalence and characteristics between men and women; even though, further research is needed to unravel additional gender-related characteristics in CKD and to identify the mechanisms of sexual dimorphism in CKD.[21]Hematological derangements are common in CKD patients, and these become most apparent as the disease progresses due to diminished EPO production, increased hemolysis, bone marrow suppression, and hematuria and gastrointestinal blood loss. Maintenance HD is the most common renal replacement treatment modality in Sub-Sahara Africa where near normal kidney function is temporarily restored. Pre- and post-dialysis hematological indices were analyzed and compared with control group in this study. The patients at pre-dialysis have significantly reduced mean ± SD of Hb concentration (6.3 ± 1.8 g/dl), RBC count (2.1 ± 1.3 × 106/ul), and platelet count (186 ± 28.2 × 103/ul) compared to control group which had 12.2 ± 1.4 g/dl, 4.4 ± 0.2 × 106/ul, and 350.5 ± 82.2 × 103/ul, respectively; while in contrast had higher lymphocyte count (39.7 ± 3.0%) when compared with the control group (37.0 ± 4.2%). Hematological indices obtained in this study are in agreement with previous studies.[22-24] At post-dialysis stage, 
Table 1: Age distribution of HD patients attending 
the dialysis center of the hospital
Age group Number of patients (%)
16–20 2 (2)
21–25 4 (4)
26–30 3 (3)
31–35 6 (6)
36–40 5 (5)
41–45 16 (16)
46–50 12 (12)
51–55 29 (29)
56–60 8 (8)
61–65 2 (2)
66–70 7 (7)
71–75 3 (3)
76–80 1 (1)
≥81 2 (2)
Total 100 (100)
HD: Hemodialysis
Table 2: Age and gender distribution of the HD 
patients and control subjects
Parameter Control subjects HD patients
Age (years) 
M 47.4±5.3 56.9±2.7
F 39.1±6.2 42.5±6.2
Gender (n)
M 30 72
F 20 28
HD: Hemodialysis
Table 3: Hematological indices of control subjects 
and HD patients at the dialysis center of the 
hospital
Parameter Mean±SD
Control 
subjects
Pre‑dialysis Post‑dialysis
PCV (%) 40.0±3.2 24.1±2.0 27.1±5.0d
Hb Concentration 
(g/dl)
12.2±1.4 6.3a±1.8 7.8±1.2d
WBC count  
(×103/ul)
6.9±3.7 6.8±2.7 7.1±0.3
RBC count  
(×106/ul)
4.4±0.2 2.1a±1.3 2.9±0.5d
Platelet 
count (×103/ul)
350.5±82.2 186.4a±28.2 185.2±56.8
Neutrophil (%) 57.8±5.2 54.7±3.2 58.3±3.8d
Basophil (%) 1.0±1.0 1.3±1.0 1.0±0.3
Eosinophil (%) 2.0±1.4 2.0±1.0 2.0±0.3
Lymphocyte (%) 37.0±4.2 39.7b±3.0 40.4±4.2
Monocyte (%) 2.0±0.5 1.0±1.0 2.0±1.0
MCV (fl) 102.8±0.6 101.3±2.2 99.8±0.8
MCH (pg) 31.5±0.3 30.7±0.9 31.2±0.2
MCHC (g/dl) 30.6±1.1 29.1±0.7 30.3±0.5
P≤0.05 is considered statistically significant, asignificantly decreased (P≤0.05) 
compared to the control, bsignificantly increased (P≤0.05) compared to the control, 
csignificantly decreased (P≤0.05) compared to the pre‑dialysis, dsignificantly 
increased (P≤0.05) compared to the pre‑dialysis. PCV: Packed cell volume, 
MCV: Mean corpuscular volume, MCH: Mean cell hemoglobin, MCHC: Mean cell 
hemoglobin concentration, WBC: White blood cell, Hb: Hemoglobin, RBC: Red blood 
cell, SD: Standard deviation, HD: Hemodialysis
Ferdinand, et al.: Pre-and post-dialysis hematological indices of patients with chronic kidney diseases www.apjhs.com
Asian Pacific Journal of Health Sciences  |  Vol. 5 | Issue 2 | April-June | 2018Page | 36
PCV (27.1 ± 5.0%), Hb concentration (7.8 ± 1.2 g/dl), RBC count (2.9 ± 0.5 × 106/ul), and neutrophil (58.3 ± 3.8%); significantly increased compared with pre-dialysis stage with PCV (24.1 ± 2.0%), Hb concentration (6.3 ± 1.8 g/dl), RBC count (2.1 ± 1.3 × 106/ul), and (54.7 ± 3.2%). Improvement in the form of increased hematological indices at post-dialysis has also been reported by previous studies.[14,25] This is, however, in contrast with the report by Dara [26] where there was no significant change in the hematological indices at the post-dialysis stage.
CONCLUSIONThere are remarkable changes in some hematological indices in chronic renal disease patients undergoing maintenance HD. A more detailed analysis of their hematological indices will provide data that will be used for the formulation of evidenced-based treatment modalities to improve the life expectancy of chronic renal disease patients.
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